You Position: Home > Paper

Comparative study of the effects of capecitabine and tegafur maintained chemotherapy for advanced gastric cancer

( views:0, downloads:0 )
Author:
No author available
Journal Title:
China Clinical Practical Medicine
Issue:
6
DOI:
10.3760/cma.j.cn115570-2020731.01092
Key Word:
卡培他滨;替吉奥;晚期胃癌;维持化学治疗;Capecitabine;Tegafur;Advanced gastric cancer;Maintenance chemotherapy

Abstract: Objective:To evaluate the clinical value of capecitabine and tegafur maintenance chemotherapy in patients with advanced gastric cancer.Methods:A total of 93 patients with advanced gastric cancer were admitted by the the first district of the depentment of gas, Jiaozuo Second People's Hospital from January 2017 to December 2018 were selected.There were 55 males and 38 females, aged(52.5±7.3)years, ranging from 34 to 78 years.According to different maintenance treatment regiments, the patients were divided into capecitabine treatment group, tegafur treatment group and blank group, with 31 patients in each group.The treatment effect and prognosis of the three groups were compared.Results:There was no statistically significant difference in the treatment effect among the three groups( P>0.05). There was no significant difference in disease progression time between capecitabine treatment group and the tegafur treatment group( P>0.05). The disease progression time of patients in the blank group[(6.2±1.3)months]was shorter than that of patients in the tegafur treatment group[(8.9±1.1)months], with statistically significant difference( P<0.05). The total survival time of capecitabine treatment group[(14.3±1.6)months] and the tegafur treatment group[(14.8±1.5)months]was significantly different from that of the blank group[(13.2±0.8)months], with statistically significant difference( P<0.05). The incidence of leukocytopenia, gastrointestinal reaction, hand-foot syndrome and stomatitis in the three groups showed no statistically significant differences( P>0.05). The incidence of fatigue and anemia among the three groups was statistically significant( P<0.05). Conclusion:Both capecitabine and tegafur maintenance chemotherapy can prolong the time of disease progression and are relatively safe in patients with advanced gastric cancer.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn